Literature DB >> 29366802

Non-coding RNAs in the reprogramming of glucose metabolism in cancer.

Ram C Shankaraiah1, Angelo Veronese2, Silvia Sabbioni3, Massimo Negrini4.   

Abstract

Proliferating cancer cells reprogram their metabolic circuitry to thrive in an environment deficient in nutrients and oxygen. Cancer cells exhibit a higher rate of glucose metabolism than normal somatic cells, which is achieved by switching from oxidative phosphorylation to aerobic glycolysis to meet the energy and metabolites demands of tumour progression. This phenomenon, which is known as the Warburg effect, has generated renewed interest in the process of glucose metabolism reprogramming in cancer cells. Several regulatory pathways along with glycolytic enzymes are responsible for the emergence of glycolytic dependence. Non-coding (nc)RNAs are a class of functional RNA molecules that are not translated into proteins but regulate target gene expression. NcRNAs have been shown to be involved in various biological processes, including glucose metabolism. In this review, we describe the regulatory role of ncRNAs-specifically, microRNAs and long ncRNAs-in the glycolytic switch and propose that ncRNA-based therapeutics can be used to inhibit the process of glucose metabolism reprogramming in cancer cells.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerobic glycolysis; Cancer glucose metabolism; Non-coding RNA; Warburg effect

Mesh:

Substances:

Year:  2018        PMID: 29366802     DOI: 10.1016/j.canlet.2018.01.048

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  MiR-183-5p Alleviates Chronic Constriction Injury-Induced Neuropathic Pain Through Inhibition of TREK-1.

Authors:  Dan-Ni Shi; Yi-Tao Yuan; Dan Ye; Lu-Mei Kang; Jing Wen; Hong-Ping Chen
Journal:  Neurochem Res       Date:  2018-05-07       Impact factor: 3.996

2.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Biomolecular Condensates and Cancer.

Authors:  Ann Boija; Isaac A Klein; Richard A Young
Journal:  Cancer Cell       Date:  2021-01-07       Impact factor: 31.743

Review 4.  Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation.

Authors:  Chelsea Schiliro; Bonnie L Firestein
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

5.  Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer.

Authors:  Zheng Li; Juan Zheng; Yang Feng; Yaming Li; Yiran Liang; Ying Liu; Xiaolong Wang; Qifeng Yang
Journal:  Cancer Med       Date:  2021-09-27       Impact factor: 4.452

6.  Resibufogenin suppresses tumor growth and Warburg effect through regulating miR-143-3p/HK2 axis in breast cancer.

Authors:  Ying Guo; Fei Liang; Fuli Zhao; Jian Zhao
Journal:  Mol Cell Biochem       Date:  2020-01-31       Impact factor: 3.842

7.  Discovery of a novel three-long non-coding RNA signature for predicting the prognosis of patients with gastric cancer.

Authors:  Yongqiang Wang; Huimin Zhang; Ju Wang
Journal:  J Gastrointest Oncol       Date:  2020-08

8.  Circ_0013359 facilitates the tumorigenicity of melanoma by regulating miR-136-5p/RAB9A axis.

Authors:  Qi Zhang; Yingfa Feng; Jiangang Feng; Jinming Zhang; Lili Huang
Journal:  Open Life Sci       Date:  2021-05-22       Impact factor: 0.938

9.  miR-493 by regulating of c-Jun targets Wnt5a/PD-L1-inducing esophageal cancer cell development.

Authors:  Wei Bian; Yishuai Li; Haiyong Zhu; Shaolin Gao; Ren Niu; Chuan Wang; Hao Zhang; Xuebo Qin; Shujun Li
Journal:  Thorac Cancer       Date:  2021-04-01       Impact factor: 3.500

10.  Circ_0001944 Contributes to Glycolysis and Tumor Growth by Upregulating NFAT5 Through Acting as a Decoy for miR-142-5p in Non-Small Cell Lung Cancer.

Authors:  Yawei Dou; Wei Tian; Hongtao Wang; Shanshan Lv
Journal:  Cancer Manag Res       Date:  2021-05-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.